-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

ASH-FDA Joint Symposium on New Drug Approvals in Malignant Hematology

Program: Special-Interest Sessions
Hematology Disease Topics & Pathways:
Diseases, Therapies
Monday, December 3, 2018: 10:30 AM-12:00 PM
Hall AB (San Diego Convention Center)
Chair:
Ann T. Farrell, MD., U.S. Food and Drug Administration
Disclosures:
No relevant conflicts of interest to declare.
This joint session, one of two co-sponsored by the U.S. Food and Drug Administration (FDA), will feature drugs recently approved to treat hematological disorders. FDA product-reviewers will discuss the safety and efficacy issues for the products' clinical trials and toxicity studies. The program will also include clinicians who will discuss their perspectives on the use of the products in the real-world setting. There will be ample time for questions from the audience.

Angelo De Claro, MD

U.S. Food and Drug Administration, Silver Spring, MD

Bindu Kanapuru, MD

U.S. Food and Drug Administration, Vienna, VA

Brian T. Hill, MD, PhD

Taussig Cancer Institute, Department of Hematology & Medical Oncology, Cleveland Clinic Foundation, Cleveland, OH; Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

Poornima Sharma, MD

U.S. Food and Drug Administration, Silver Spring, MD

Christopher R Flowers, MD, MS

Division of Bone Marrow and Stem Cell Transplantation, Winship Cancer Institute of Emory University, Atlanta, GA

Kelly J. Norsworthy, MD

U.S. Food and Drug Administration, Severna Park, MD; U.S. Food and Drug Administration, Silver Spring, MD

Courtney D. DiNardo, MD, MSc

Department of Leukemia, UT MD Anderson Cancer Center, Houston, TX